Respiratory imaging technology company 4DMedical (ASX:4DX) has raised $150 million through an institutional placement at $3.80 per share, supported by new global institutional investors and strong backing from existing shareholders.
The capital raise, structured as a $79.1 million placement of new shares and a $70.9 million block trade of shares previously issued to Alpha Investment Partners, limits dilution to just 3.86%.
Proceeds will primarily fund the commercialisation of 4DMedical's CT:VQ technology across US academic medical centres, following rapid adoption at Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health.
Concurrently, CEO Andreas Fouras and CFO Julian Sutton have exercised options, increasing their shareholdings and contributing $6.9 million in additional capital to the company.
With a pro forma cash position exceeding $200 million, 4DMedical is positioned to expand its product portfolio, strengthen its U.S. market presence, and drive the business toward profitability.